Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATEC NASDAQ:CODX NASDAQ:CTSO NASDAQ:IRMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATECAlphatec$8.13-1.6%$9.24$6.82▼$23.29$1.27B0.882.52 million shs1.56 million shsCODXCo-Diagnostics$4.88+8.4%$3.01$1.26▼$46.50$16.58M2.7416.51 million shs556,732 shsCTSOCytosorbents$0.41-2.7%$0.55$0.40▼$1.39$26.53M1.35166,608 shs76,841 shsIRMDiRadimed$96.00-0.4%$90.95$55.11▼$107.90$1.23B0.91140,739 shs153,649 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATECAlphatec-1.57%+5.86%+16.31%-34.96%-33.42%CODXCo-Diagnostics+8.44%-5.61%+156.84%+85.55%-44.22%CTSOCytosorbents-2.72%-15.95%-34.76%-43.37%-61.23%IRMDiRadimed-0.44%+5.36%+13.85%-3.39%+60.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATECAlphatec$8.13-1.6%$9.24$6.82▼$23.29$1.27B0.882.52 million shs1.56 million shsCODXCo-Diagnostics$4.88+8.4%$3.01$1.26▼$46.50$16.58M2.7416.51 million shs556,732 shsCTSOCytosorbents$0.41-2.7%$0.55$0.40▼$1.39$26.53M1.35166,608 shs76,841 shsIRMDiRadimed$96.00-0.4%$90.95$55.11▼$107.90$1.23B0.91140,739 shs153,649 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATECAlphatec-1.57%+5.86%+16.31%-34.96%-33.42%CODXCo-Diagnostics+8.44%-5.61%+156.84%+85.55%-44.22%CTSOCytosorbents-2.72%-15.95%-34.76%-43.37%-61.23%IRMDiRadimed-0.44%+5.36%+13.85%-3.39%+60.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATECAlphatec 2.75Moderate Buy$18.58128.58% UpsideCODXCo-Diagnostics 2.00Hold$67.501,283.20% UpsideCTSOCytosorbents 2.00Hold$5.381,207.79% UpsideIRMDiRadimed 3.00Buy$120.0025.00% UpsideCurrent Analyst Ratings BreakdownLatest CTSO, IRMD, ATEC, and CODX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026CODXCo-Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/20/2026IRMDiRadimed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/7/2026ATECAlphatec BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$27.00 ➝ $24.005/7/2026ATECAlphatec Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$28.00 ➝ $14.005/7/2026ATECAlphatec HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.005/6/2026ATECAlphatec Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/6/2026IRMDiRadimed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/6/2026ATECAlphatec Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/6/2026ATECAlphatec Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $23.005/6/2026ATECAlphatec Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$25.00 ➝ $14.005/6/2026ATECAlphatec BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$27.00 ➝ $24.00(Data available from 6/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATECAlphatec$764.16M1.64N/AN/A$0.08 per share101.63CODXCo-Diagnostics$620K29.04N/AN/A$9.14 per share0.53CTSOCytosorbents$37.06M0.70N/AN/A$0.09 per share4.57IRMDiRadimed$86.28M14.22$1.85 per share51.87$7.44 per share12.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATECAlphatec-$143.36M-$0.82N/A162.60N/A-15.93%-1,183.84%-15.83%7/30/2026 (Estimated)CODXCo-Diagnostics-$46.90M-$15.77N/AN/AN/A-6,760.63%-164.92%-141.15%8/14/2026 (Estimated)CTSOCytosorbents-$8.20M-$0.19N/A13.70N/A-31.85%-235.57%-37.88%8/6/2026 (Estimated)IRMDiRadimed$22.48M$1.8352.46N/AN/A27.36%24.48%21.25%7/30/2026 (Estimated)Latest CTSO, IRMD, ATEC, and CODX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CODXCo-Diagnostics-$3.75-$4.06-$0.31-$4.06$0.13 million$0.15 million5/13/2026Q1 2026CTSOCytosorbents-$0.06-$0.08-$0.02-$0.08$9.40 million$8.86 million5/5/2026Q1 2026ATECAlphatec-$0.01-$0.22-$0.21-$0.22$197.51 million$192.11 million5/1/2026Q1 2026IRMDiRadimed$0.46$0.49+$0.03$0.45$21.32 million$21.98 million3/31/2026Q4 2025CODXCo-Diagnostics-$3.90-$16.65-$12.75-$16.65$0.13 million$0.26 million3/25/2026Q4 2025CTSOCytosorbents-$0.05-$0.09-$0.04-$0.09$9.22 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATECAlphatecN/AN/AN/AN/AN/ACODXCo-DiagnosticsN/AN/AN/AN/AN/ACTSOCytosorbentsN/AN/AN/AN/AN/AIRMDiRadimed$0.800.83%N/A43.72%1 YearsLatest CTSO, IRMD, ATEC, and CODX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026IRMDiRadimedquarterly$0.200.93%5/15/20265/15/20265/29/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATECAlphatec40.351.901.12CODXCo-DiagnosticsN/A2.282.09CTSOCytosorbents4.701.090.81IRMDiRadimedN/A7.136.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATECAlphatec66.35%CODXCo-Diagnostics14.99%CTSOCytosorbents32.87%IRMDiRadimed92.34%Insider OwnershipCompanyInsider OwnershipATECAlphatec13.48%CODXCo-Diagnostics5.40%CTSOCytosorbents7.30%IRMDiRadimed36.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATECAlphatec700153.79 million133.06 millionOptionableCODXCo-Diagnostics1003.69 million3.49 millionOptionableCTSOCytosorbents22062.79 million58.21 millionOptionableIRMDiRadimed11012.78 million8.08 millionOptionableCTSO, IRMD, CODX, and ATEC HeadlinesRecent News About These CompaniesAssessing IRADIMED (IRMD) Valuation After Strong Multi Year Returns And A Premium P/E MultipleJune 3, 2026 | finance.yahoo.comiRadimed (NASDAQ:IRMD) CEO Sells $226,500.00 in StockJune 3, 2026 | insidertrades.comIRADIMED's CEO Is Selling Steadily — The Plan, Not the Stock, Is Driving ItJune 2, 2026 | aol.comAIradimed Corp (IRMD): 3 Things That Stood Out From Q1 ReportMay 28, 2026 | finance.yahoo.comIradimed’s CEO and Founder Sold 7,500 Company Shares. What Does That Mean for Investors?May 27, 2026 | aol.comAIRadimed Rides 3870 Momentum Despite Near-Term DipMay 25, 2026 | theglobeandmail.comiRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 2,500 SharesMay 21, 2026 | insidertrades.comIRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceMay 20, 2026 | globenewswire.comIradimed Corp Eyes 2026 Surge After Strong QuarterMay 14, 2026 | theglobeandmail.comiRadimed (NASDAQ:IRMD) CEO Sells $261,144.06 in StockMay 14, 2026 | insidertrades.comiRadimed Stock Dividends | NASDAQ:IRMD | BenzingaMay 13, 2026 | benzinga.comReaffirmed Outlook And Dividend: What Does IRMD’s Confidence Signal About Its MRI Pump Moat?May 13, 2026 | finance.yahoo.comHere's What We Like About IRADIMED's (NASDAQ:IRMD) Upcoming DividendMay 12, 2026 | finance.yahoo.comA Look At IRADIMED (IRMD) Valuation As Long Term Returns Contrast With Recent Share Price WeaknessMay 7, 2026 | finance.yahoo.comiRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 3,750 SharesMay 7, 2026 | insidertrades.comIRadimed Corporation (NASDAQ:IRMD) Q1 2026 Earnings Call TranscriptMay 5, 2026 | insidermonkey.comiRadimed Corp (IRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and New Product DemandMay 2, 2026 | finance.yahoo.comIRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call TranscriptMay 1, 2026 | seekingalpha.comiRadimed (IRMD) Beats Q1 Earnings and Revenue EstimatesMay 1, 2026 | zacks.comIRADIMED CORPORATION Reports First Quarter 2026 Financial ResultsMay 1, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Is Co-Diagnostics National Security’s Next Diagnostic Pick?By Jeffrey Neal Johnson | May 28, 2026CTSO, IRMD, CODX, and ATEC Company DescriptionsAlphatec NASDAQ:ATEC$8.13 -0.13 (-1.57%) Closing price 06/10/2026 04:00 PM EasternExtended Trading$8.18 +0.05 (+0.66%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.Co-Diagnostics NASDAQ:CODX$4.88 +0.38 (+8.44%) Closing price 06/10/2026 04:00 PM EasternExtended Trading$4.80 -0.08 (-1.54%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Cytosorbents NASDAQ:CTSO$0.41 -0.01 (-2.72%) Closing price 06/10/2026 04:00 PM EasternExtended Trading$0.42 +0.01 (+1.70%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.iRadimed NASDAQ:IRMD$96.00 -0.42 (-0.44%) Closing price 06/10/2026 04:00 PM EasternExtended Trading$96.06 +0.06 (+0.06%) As of 07:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Biggest Opportunity From SpaceX’s IPO May Surprise You Chewy’s Growth Engine Is Stronger Than the Market Thinks Everpure: AI Storage Uncertainty Overshadows Breakneck Growth As Shares Fall, Analyst Are Boosting their Broadcom Price Targets This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason FuelCell Energy Just Got a Wake-Up Call From Wall Street Intel Is the Market's Most Mispriced AI Hedge Palantir's AIPCon Shows Why Customers Are Fueling the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
